In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Co-Diagnostics (CODX – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $1.33.
According to TipRanks, Chen is an analyst with an average return of -27.4% and a 25.56% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Prophase Labs, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Co-Diagnostics with a $3.00 average price target.
See the top stocks recommended by analysts >>
CODX market cap is currently $40.74M and has a P/E ratio of -1.29.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CODX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company’s products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Read More on CODX:
